In this section
@article{Chu:2001:10.1210/jcem.86.5.7457,
author = {Chu, LW and Lam, KS and Tam, SC and Hu, WJ and Hui, SL and Chiu, A and Chiu, KC and Ng, P},
doi = {10.1210/jcem.86.5.7457},
journal = {J Clin Endocrinol Metab},
pages = {1913--1920},
title = {A randomized controlled trial of low-dose recombinant human growth hormone in the treatment of malnourished elderly medical patients.},
url = {http://dx.doi.org/10.1210/jcem.86.5.7457},
volume = {86},
year = {2001}
}
TY - JOUR
AB - High-dose recombinant human GH (rhGH) has been shown to improve the nutritional status of malnourished older adults. It is uncertain whether low-dose rhGH is effective and whether its effect on nutritional status will lead to any improvement in physical function. There is also no data on the outcome after a short course of rhGH treatment. The objectives of this study were to determine the efficacy of low-dose rhGH treatment for 4 weeks in malnourished elderly patients, its effect on physical functions, and the intermediate term outcome after a 4-week rhGH treatment. The study design was a randomized, placebo-controlled, double-blind trial conducted in a university teaching hospital. The patients were 19 medically stable malnourished elderly subjects. Intervention in the rhGH group was as follows: rhGH (Saizen, Serono, Switzerland) 0.09 IU/kg body weight (BW) 3 times weekly were given together with appropriate dietary intervention as prescribed by the dietitian. In the placebo group, equal volumes of normal saline per kilogram BW were given 3 times weekly together with the dietary intervention. The baseline demographic, anthropometric, nutritional, and hematological variables, measures of physical function, and insulin-like growth factor I levels in both groups were comparable. Compared with the placebo group, the GH-treated group showed a more rapid gain in BW (after 3 weeks, +1.27 +/- 0.36 vs. -0.28 +/- 0.37 kg; P = 0.008), total lean body mass (change after 3 weeks by bio-impedance analysis, +1.45 +/- 0.36 vs. -0.37 +/- 0.48 kg; P = 0.009) and a faster improvement in 5-m walking time (decrease after 4 weeks, 23.79 +/- 9.41 vs. 0.45 +/- 4.62 sec; P = 0.047). The hemoglobin level rose more in the rhGH than the placebo groups (change at 8 weeks, +0.84 +/- 0.34 vs. -0.42 +/- 0.29 g/dL; P = 0.012). Serum albumin level also showed a greater delayed increase in the rhGH group than in the placebo group (change at 8 weeks, +5.1 +/- 0.8 vs. 1.6 +/- 1.2 g/dL; P = 0.023). The
AU - Chu,LW
AU - Lam,KS
AU - Tam,SC
AU - Hu,WJ
AU - Hui,SL
AU - Chiu,A
AU - Chiu,KC
AU - Ng,P
DO - 10.1210/jcem.86.5.7457
EP - 1920
PY - 2001///
SN - 0021-972X
SP - 1913
TI - A randomized controlled trial of low-dose recombinant human growth hormone in the treatment of malnourished elderly medical patients.
T2 - J Clin Endocrinol Metab
UR - http://dx.doi.org/10.1210/jcem.86.5.7457
UR - https://www.ncbi.nlm.nih.gov/pubmed/11344184
VL - 86
ER -